Recent Transactions

27-Sep-23
Undisclosed
United States flag
Target: 

Slayback Pharma LLC

United States flag
Acquiror: 
Azurity Pharmaceuticals

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

26-Apr-23
Pending
$127 million
Australia flag
Target: 

Marley Spoon business combination with 468 SPAC II

Germany flag
Acquiror: 
468 SPAC II SE

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

02-Sep-22
Pending
$205 million
United Kingdom flag
Target: 

brsk

United States flag
Acquiror: 
Ares Management

Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager

19-Aug-22
$2.2 billion
United States flag
Target: 

GI Alliance

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

01-Jun-22
$537 million
Ireland flag
Target: 

NAC 33 & NAC 34, subsidiaries of Nordic Aviation Capital

United States flag
Acquiror: 
Azorra Aviation

Advised Azorra Aviation, a leading commercial aircraft lessor backed by Oaktree Capital Management, on the chapter 11 restructuring and related investment in NAC 33 & 34, two exiting subsidiaries of Nordic Aviation Capital

05-May-22
Undisclosed
United States flag
Target: 

Airtower Networks

Acquiror: 
DIF Capital Partners

Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners

08-Apr-22
$364 million
United Kingdom flag
Target: 

Netomnia

United States flag
Acquiror: 
DigitalBridge Investment Management, Advencap, SoHo Square

Advised Netomnia, a leading UK-based fiber operator, on its £295m fundraise led by DigitalBridge Investment Management with follow-on commitments from existing shareholders Soho Square Capital LLP and Advencap Limited

15-Nov-21
$166 million
United Kingdom flag
Target: 

Netomnia

flag not available
Acquiror: 
Avenue Capital, Advencap

Advised Netomnia, a UK-based fibre operator, on its first large-scale fundraise of £123m 

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

09-Feb-21
Undisclosed
United States flag
Target: 

US Acute Care Solutions

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson

01-Oct-20
$1.05 billion
United States flag
Target: 

Akorn, Inc.

flag not available
Acquiror: 
First Lien Term Loan Lenders

Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization

02-Nov-18
$NA
United States flag
Target: 

Pinnacle Midstream

United States flag
Acquiror: 
EagleClaw Midstream

Advised I Squared Capital on the contribution of Pinnacle Midstream, its Delaware Basin Midstream Company, to EagleClaw Midstream as part of the formation of a leading Delaware Basin Midstream Partnership with EagleClaw Midstream and Blackstone Energy Partners

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

29-Nov-17
$NA
United States flag
Target: 

Substantially all of the gas production and midstream assets of Energy Corporation of America

United States flag
Acquiror: 
Greylock Energy

Advised Energy Corporation of America, a natural gas producer focused on the Marcellus Shale, on the sale of substantially all its gas production and midstream assets to Greylock Energy, an affiliate of ArcLight Capital Partners

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

26-May-16
$500 million
Egypt, U.S. flags
Target: 

Apex International Energy Management LLC

flag not available

Advised Apex International Energy Management, a newly formed oil and gas venture focused on the Middle East and North Africa regions, in the private equity fund-raising process with multiple energy-focused financial sponsors, ultimately resulting in an initial $500 million capital commitment from Warburg Pincus.

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

24-Feb-15
$NA
Luxembourg flag
Target: 

Azelis Group (majority owned by 3i)

United Kingdom flag
Acquiror: 
Funds advised by Apax Partners

Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners

11-Dec-12
$862 million
United States flag
Target: 

TNS, Inc.

United States flag
Acquiror: 
Siris Capital Group

Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

Pages

show all